SciBase Receives Initial Order for Clinical Study with Castle Biosciences

September 23, 2025
SciBase has received an initial order for a clinical study from Castle Biosciences, marking the start of their collaboration to develop a test for atopic dermatitis.

SciBase has received an initial order for a clinical study from Castle Biosciences, as announced in a press release. The order, valued at approximately $0.8 million, includes Nevisense Go devices and electrodes. This marks the beginning of their collaboration to develop a test predicting flares in patients with atopic dermatitis.

The collaboration, initially announced in June 2025, involves a license agreement between the two companies. Deliveries for the clinical study are set to begin in the fourth quarter of 2025. Castle Biosciences has also invested in SciBase, becoming its second-largest shareholder. Pia Renaudin, CEO of SciBase, expressed enthusiasm about the collaboration's potential to improve therapies for patients with skin barrier dysfunctions.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

09/23
Kipu Health and Team Recovery Partner to Enhance Addiction Treatment
09/23
rater8 Launches Visibility Engine for Healthcare Providers
09/23
Bunkerhill Health's AI Algorithm Gains FDA Clearance for Heart Failure Detection
09/23
Heartline Launches AI-Powered Home Health Assistant
09/23
TegMine and Boehringer Ingelheim Collaborate on Cancer Antibody System

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Stanford HAI’s 2025 AI Index Reveals Record Growth in AI Capabilities, Investment, and Regulation

The 2025 AI Index by Stanford HAI provides a comprehensive overview of the global state of artificial intelligence, highlighting significant advancements in AI capabilities, investment, and regulation. The report details improvements in AI performance, increased adoption in various sectors, and the growing global optimism towards AI, despite ongoing challenges in reasoning and trust. It serves as a critical resource for policymakers, researchers, and industry leaders to understand AI's rapid evolution and its implications.

Read more

You May Also Like